$TNTY breaches lower bolliesThe candles breached the lower bollie yesterday by more than 50% signaling a 85% likelyhood for a correction with the MACD and STO supporting my idea.
PHARMA
Aurobindo Pharma - Excellent buy at current levels!Aurobindo Pharma is another great company one should have in their investment portfolio and this is a very good time to buy/add this stock around 580-600 levels.
Expecting it to give 20% + returns annually from here and wouldn't be surprised if it is much more than that..
$CTRV 1st Conference Starts Tmrw Continues in the Right DrtnNothing entirely new to report. Closed above last major resistance and still continues to stair step in the right direction. I think it should be noted and I didn't mention it before but the corporations who took a stake in the company in the last two months:
Maxim Group set a $4.00 price target on shares of ContraVir Pharmaceuticals and gave the stock a “buy” rating in a research report on Tuesday, April 11th. Noble Financial reaffirmed a “Buy” rating on shares of ContraVir Pharmaceuticals in a research report on Friday, April 21st.
Teachers Advisors LLC boosted its position by 3.1% in the fourth quarter. Teachers Advisors LLC now owns 298,781 shares worth $1,820,000
Vanguard Group Inc. boosted its position in ContraVir Pharmaceuticals by 10.2% in the first quarter. Vanguard Group Inc. now owns 2,048,283 shares worth $3,626,000 after buying an additional 189,634 shares during the last quarter.
Geode Capital Management LLC boosted its position by 2.0% in the first quarter. Geode Capital Management LLC now owns 353,777 shares worth $626,000 after buying an additional 7,057 shares during the last quarter.
Morgan Stanley boosted its position in ContraVir Pharmaceuticals by 0.4% in the first quarter. Morgan Stanley now owns 278,798 shares worth $493,000 after buying an additional 1,119 shares during the last quarter.
5.49% of the stock is owned by institutional investors.
Very nice averages stakes taken by numerous groups and this is a month or two before the conferences. Shows some agencies might have gotten a sneak peak at the upcoming info. $CTRV
Newest Alert is $CBIO$CBIO Recent Highlights and Upcoming Milestones
Recent Highlights:
Catalyst Biosciences’ Factor IX Recommended for Orphan Drug Designation in Europe
Contract revenue for the three months ended March 31, 2017 was $0.3 million, compared with $0.1 million for the prior year period. The increase in contract revenue was due to the milestone revenue from ISU Abxis of $0.2 million.
Cash, cash equivalents and short-term investments as of March 31, 2017 were $14.5 million
The Company believes that its existing capital resources will be sufficient to meet its projected operating requirements for at least the next 12 months.
Raised $20.7 million through an underwritten public equity offering that included the full exercise of the underwriters’ over-allotment option to purchase additional shares and warrants on April 12, 2017
Achieved key milestones with CB 2679d/ISU304, the Company’s next-generation coagulation Factor IX, as follows:
Investigational New Drug (IND) application approved by the Korean Ministry of Food and Drug Safety (MFDS)
Completion of IND-enabling toxicology studies triggered a milestone payment from Catalyst’s collaboration partner, ISU Abxis
Advanced the development of marzeptacog alfa (activated), the Company’s next-generation Factor VIIa, including the following accomplishments:
Received notice from the European Patent Office that the opposition period, for a patent granted to Catalyst, has expired and no opposition has been filed
Selected a global contract research organization, INC Research, to conduct the Phase 2/3 efficacy clinical trial of marzeptacog alfa (activated) in individuals with hemophilia A or B with an inhibitor
Anticipated Milestones
CB 2679d/ISU304: Initiate a Phase 1/2 proof-of-concept clinical trial in individuals with severe hemophilia B in the second quarter of 2017; the trial will be conducted by Catalyst’s collaborator, ISU Abxis (KOSDAQ: 086890) in South Korea
Marzeptacog alfa (activated): Initiate the Phase 2 part of a Phase 2/3 efficacy clinical trial in individuals with hemophilia A or B with an inhibitor in the fourth quarter of 2017
Lupin is a Good Buy at current levels!Lupin is one of the top Pharma companies with an excellent Balance Sheet, Sales Revenue growth and a very good future.
From long term investment point of view, this is an excellent company to have in your portfolio and current levels of 1250 are an excellent entry.
One can add more if it dips further as this stock itself promises to give 20% + returns within or much before an year..
Technically.. Weekly charts shows Fibonacci retracements to 50% and good chances of a bounce from here very soon...
Buying buying buyingCan't get enough VDRM at these prices!
Anyone who has been following my posts knows I'm very long on this stock and coming back down to these prices is a pure gift.
With the CEO speaking at a large conference at the end of the month, lots of eyes will be on this company.
$$'s by December or sooner IMO.
Millionaires will be made!
TEVA H&S formation - price preparing to turnThe $TEVA chart just keeps getting better and better....
Quarterly chart is rejecting last 2 major lows with a pinbar with stoch RSI overbought
Ideally we bounce here to retest the fibs and form a right shoulder before complete capitulation.
If the H&S formation is confirmed $TEVA should head down to levels we haven't seen since the 90's ($10 and below)
VDRM long and strong!Posted about this one a few weeks and am still holding all my shares plus a few more.
This will be 2017's big winner IMO. Low floaters move FAST. The company has revolutionary patents pending as well as great news released last Friday about their new products.
It's extremely undervalued, and I know for a fact strong hands like myself will continue buying up the float.
As I said before, millionaires will be made with this one. Don't get left n the sidelines!
Regeneron in ProfitWe expected a bounce and here we got one.
It's really early in the trade but a good sign of beeing already in profit.
On weakness, I will watch price action and maybe add to my position.
IBB likely to repeat a rally IBB went through a small rally today and we do notice there is a similar pattern happened before in the green box. It's likely to revisit 282.5-286. Let's watch to see how'd IBB go tomorrow!!
Possible H&S within TEVA?We appear to be bottoming at the neckline of a potential H&S. This thing is a monster and can be easily seen on the 6 month and yearly time frames.
You could buy the relief rally that takes us back up or wait for extra confirmation and sell the relief rally with a formation of that shoulder.
Possible double top @ 0.02415/10/5 minute charts show double top @ 0.024.
Going to hold this one but could be an indicator that we are going down.
$1.25 Price target (65k shares)2017 price target is $1.25, analysis shows me we should reach 1.25 or higher in the next 12 months. I had to sell $RNVA for +10% here as this play is too good to pass up. Company is EXTREMELY undervalued given the things in the work for 2017. Several patents, topical Viagra in the works, entrance into the Medical Marijuana sector...Company should also fair well and benefit from the repeal of Obamacare. This will be one to watch, lock in profits don't get emotional. Good money to be made long term.
GILD Long, Bargain Price, Monthly MACD Looks BeautifulIf you check the ideas I´ve posted, you can see the monthly GILD chart, were you can clearly see the stock is about to blow up and at a great entry price.
Right here you can see how the stock made 3 resistance levels, a few weeks ago it validated the second resistance and it just did with the first one.
Enter now or regret it later.
Go big or go home.
Aurobindo Pharma, Dark horse among Pharma Space, Accumulate!!Ongoing Pharma/Drug Stance from Trump may force Indian Pharma Space into a short term downtrend, Aurobindo's foothold is strong in Europe than US, they plan to expand more in Europe than US. if available within Accumulation range, one should buy and hold for medium to long term!!
$KBIO Long12.5.2016- $KBIO currently trading at 4.25. Potential once they receive PRV (Priority Review Voucher) for Benznidazole possibility for trading at $5-6. Stock jumped about $1 due to the Letter to Stakeholders by Dr. Cameron Durrant. I expect this stock to rise.
Disclosure: I am long $KBIO
SEE MORE: globenewswire.com
Shire (Pre Election) Pharmaceuticals shares have been hit hard since Clinton's public disapproval of Pharmaceuticals Co.'s prices and profits. Pharmaceuticals shares in general have declined across the board. which is evident in the H1 chart of Shire.
R4 5155.88
R3 4985.27
R2 downward trendline
R1 4634.31
Current 4580.50
S1 4317.47
If Clinton wins I believe we will enter a new lower distribution.
ZTS. Pullback Then DropTrendline support was broken.
Now the price is making a pullback to the broken trend.
Risk trade to sell closer to trendline.
Less risky to sell on break of the first trigger.
Target 38.
